Blog
RSS FeedPosted by Michael Wonder on 04 Dec 2022
Anti-viral drug should not be first choice in treating COVID-19
3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for ...
Posted by Michael Wonder on 02 Dec 2022
Agenda for the December 2022 PBAC intracycle meeting
2 December 2022 - The agenda for the December 2022 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 01 Dec 2022
Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
1 December 2022 - At a time when many Americans are clamouring for more transparency into prescription drug pricing, one ...
Posted by Michael Wonder on 01 Dec 2022
Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
Posted by Michael Wonder on 01 Dec 2022
‘Good news’ for Kiwi women as PHARMAC funds Utrogestan from today
1 December 2022 - The end of a decade long wait. ...
Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...
Posted by Michael Wonder on 01 Dec 2022
Takeda Korea's Kynteles SC wins insurance benefit
1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...
Posted by Michael Wonder on 01 Dec 2022
Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
Posted by Michael Wonder on 01 Dec 2022
Citius Pharmaceuticals announces US FDA acceptance of biologics license application of denileukin diftitox for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma
1 December 2022 - PDUFA target action date is 28 September 2023. ...
Posted by Michael Wonder on 01 Dec 2022
FDA grants fast track designation to Nuvectis Pharma's NXP800 for the treatment of platinum-resistant, ARID1A mutated ovarian carcinoma
1 December 2022 - Nuvectis Pharma today announced that the US FDA has granted fast track designation to NXP800 for the ...
Posted by Michael Wonder on 01 Dec 2022
Scynexis announces FDA approval of second indication for Brexafemme (ibrexafungerp) for reduction in incidence of recurrent vulvovaginal candidiasis
1 December 2022 - Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant superiority of ibrexafungerp over ...
Posted by Michael Wonder on 01 Dec 2022
Oncolytics Biotech receives FDA fast track designation for the treatment of advanced/metastatic pancreatic cancer
1 December 2022 - FDA fast rack designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective ...
Posted by Michael Wonder on 01 Dec 2022
Aurinia announces the Great Britain marketing authorisation of Lupkynis (voclosporin) for the treatment of lupus nephritis
30 November 2022 - MHRA Approval follows European Commission marketing authorisation of Lupkynis to treat adults with active lupus nephritis in ...
Posted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 01 Dec 2022
Innoviva announces FDA acceptance and priority review of new drug application for sulbactam-durlobactam
30 November 2022 - Sulbactam-durlobactam is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii, ...